Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06037252 · ClinicalTrials.gov registry record · Phase 2
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
A Phase 2 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 414
- Enrollment target
- 20
- Study locations
NCT06037252 is a Phase 2 study of Obesity and Type 2 Diabetes that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 414 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06037252, a Phase 2 study of Obesity and Type 2 Diabetes, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 414 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (20)
California
- John Muir Physician Network Research Center - Concord
- Care Access - Sacramento - Sacramento
Florida
- Retreat Medical Research - Miami
- American Research Centers of Florida - Pembroke Pines
Georgia
- Alta Pharmaceutical Research Center - Norcross
- AGILE Clinical Research Trials, LLC - Sandy Springs
Texas
- Juno Research - Houston
- Southern Endocrinology Associates - Mesquite
Arizona
- Medical Advancement Centers of Arizona - Phoenix
Colorado
- Care Access - Aurora - Aurora
Connecticut
- Chase Medical Research, LLC - Waterbury
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 414 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06037252
The ClinicalTrials.gov registry entry for NCT06037252 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 414 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (49% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06037252 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06037252 about?
NCT06037252 is a clinical study titled "A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity". The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
What is the current status of trial NCT06037252?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 414 participants. The study started on 2023-09-21. Estimated completion is 2026-10.
What conditions does trial NCT06037252 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes.
What interventions are being tested in trial NCT06037252?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06037252?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06037252 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.